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Abstract 
Purpose: To investigate the role of bone marrow kinase in chromosome X (BMX) in colorectal cancer 
(CRC) cell resistance to ABC294640 treatment. 
Methods: HCT-116R, LS174T and WiDr cells were transfected with either BMX-specific siRNA or 
scrambled siRNA, and then BMX mRNA and protein expressions were detected by quantitative 
polymerase chain reaction (qPCR) and western blotting, respectively. The cells were treated with 
ABC294640 and cell viability evaluated using cell counting and colony formation assays. Apoptosis was 
determined by detecting caspase 3/7 activity. To evaluate tumor growth of HCT-116R cells, a xenograft 
model was utilized to measure tumor size. 
Results: Pharmacological inhibition of sphingosine kinase type 2 (SK2) with ABC294640 significantly 
decreased cell viability (p < 0.001) when compared with control group. SK2 inhibition also remarkably 
induced apoptosis in HCT-116 CRC cells in a dose-dependent manner (p < 0.01 and p < 0.001). 
However, no significant effects were observed in HCT-116R, LS174T, or WiDr cells following 
ABC294640 treatment. BMX mRNA and protein expression increased in ABC294640-resistant cell 
lines. In addition, silencing BMX expression with siRNA potentiated ABC294640-induced inhibition of 
tumor growth in CRC cells in vitro and in vivo.  
Conclusion: ABC294640-induced BMX upregulation impedes the antitumor effect of ABC294640 in 
CRC cells. Therefore, these results may provide a novel therapeutic strategy for CRC using a 
combination of ABC294640 treatment and BMX blockade. 
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Colorectal cancer (CRC) is one of the most 
common malignancies, ranking second in 
incidence and mortality among all types of 
malignant worldwide [1]. Without reliable 
biomarkers, diagnosis of CRC usually occurs in 
the advanced stage, leading to high mortality in 
these patients. Currently, surgery and 
conventional chemotherapy remain the primary 
treatments for CRC [2]. However, tumor relapse 
and/or metastasis severely limit their clinical 
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effectiveness, which demonstrates that finding 
effective cancer therapies remains an important 
medical challenge [3]. Therefore, more 
investigation of mechanisms of CRC 
pathogenesis is needed to develop effective 
treatments for CRC. 
 
Sphingosine 1-phosphate (S1P) is a pleiotropic 
molecule and involved in various intracellular 
functions, including cell survival, cell motility, and 
angiogenesis [4]. S1P is formed via sphingosine 
phosphorylation by sphingosine kinase type 1 
(SK1) and sphingosine kinase type 2 (SK2) [5]. 
The two kinases are highly conserved but have 
different subcellular localizations functions, and 
pharmacology [6]. Initially, overexpression of 
SK2 was reported to induce apoptosis, mediated 
by its BH3 domain [7]. Subsequently, it was 
found that SK2 downregulation had dramatic 
antitumor function in several tumor types, 
including colon cancer [8]. Loss of SK2 had 
stronger anticancer effects than suppression of 
SK1, providing a rationale for targeting SK2 in 
cancer therapy [9]. ABC294640 is an inhibitor of 
SK2 which showed very good bioavailability 
when administered orally as well as a favorable 
safety profile in various pre-clinical models [10, 
11]. However, the drug resistance of cancer cell 
to ABC294640 is not clear.  
 
Bone marrow kinase in chromosome X (BMX) is 
a member of Tec family [12]. It has two critical 
domains, a PH-like domain that mediates 
membrane binding and an SH2 domain important 
for the binding of tyrosine-phosphorylated 
proteins [13]. BMX is regulated by several 
oncogenes such as Src and phosphoinositide 3-
kinase (PI3K), and is activated by inflammatory 
pathways [14]. It been implicated in tumor 
progression in prostate cancer, bladder cancer, 
and glioblastoma [15]. Additionally, BMX is 
reported to be involved in drug resistance. For 
example, overexpression of BMX abolished the 
miR-495-induced inhibition of drug resistance 
[16]. In addition, it suppressed the ephrin 
receptor A3 (EPHA3)-induced drug sensitivity of 
small cell lung cancer [17]. In the present study, 
the effect of BMX on the CRC response to 




siRNA and transfection 
 
HCT-116R, LS174T and WiDr cells (3×105 
cells/well) were cultured in 6-well plates 
overnight. Then the cells were transfected with 
either BMX-specific siRNA or scrambled siRNA 
(30 nM; Ribo-Bio, China) using lipofectamine 
3000 (Thermo Fisher Scientific, Waltham, MA, 
USA) according to the manufacturer’s 
instructions. The protein and RNA were extracted 
after transfection. BMX siRNA sequences were 
as follows: GUACCAGUCUAGCGCAAUAUU 
(sense) and UAUUGCGCUAGACUGGUACUU 
(anti-sense). 
 
Quantitative RT-PCR (qPCR) 
 
In accordance with the specifications, total RNA 
was isolated using TRIzol reagent (Invitrogen). 
Reverse transcription of RNA was carried out 
with a first strand cDNA kit (Sigma, Munich, 
Germany) followed by PCR amplification with a 
SYBR Green PCR kit (Thermo Fisher Scientific) 
run on an ABI 7300 Thermocycler (Thermo 
Fisher Scientific). The primers were as following: 
β-actin Forward: 5’-AAGGCCAACCGCGAGAAG 
AT-3’; and Reverse:5’-TGATGACCTGGCCGTC 
AGG-3’; BMX Forward:5’-GAGCCGAAGTCA 
GTGGTTGA-3’; and Reverse: 5’-ACTTCCCGTC 
CACGAAGAAC-3’. Differences in relative mRNA 
expression were calculated with the 2-ΔΔCt 
method [18]. 
 
Caspase 3/7 activity assay 
 
For detection of apoptosis, caspase-Glo® 3/7 
Assay kit from Promega was used. Cells (5×103 
cells/well) were cultured in 96-well plates and 
treated with either ABC294640 (0.3 or 3 μM) or 
left untreated for 48 hr. The Caspase-Glo® 3/7 
Reagent was added directly into the wells 
followed by the luminometer readings. 
 
Protein isolation and western blot analysis 
 
Cells were lysed with ice cell lysis buffer from cell 
Signaling Technology (Danvers, MA, USA).  
Protein was quantified using a bicinchoninic acid 
assay kit (EMD Millipore, Billerica, MA, USA). 
Total protein was subjected to 10 % SDS 
polyacrylamide gel electrophoresis and were 
transferred onto PVDF membranes. Membranes 
were probed with specific antibodies at 4 °C 
overnight (anti-GAPDH, 1:5000 dilution, 
#D16H11; anti-BMX, 1:1000 dilution, #24773, 
Cell Signaling Technology). The membranes 
were then incubated with secondary antibodies 
at room temperature for 2 h (1:5,000 dilution; 
#7074, Cell Signaling Technology). Bands were 
visualized using RapidStep™ ECL Reagent 
(EMD Millipore). 
 
Tumor xenografts  
 
Six-week old nude mice (Charles River 
Laboratories) received a single subcutaneous 
injection of 1×106 HCT-116R cells in the right 
flank. Tumor volumes were assessed with digital 
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calipers and calculated as previously described 
[19]. Tumors were measured 3 times weekly, 
including total mouse weights. At the end of the 
study, the tumors were excised, and weighed. 
The study was approved by Animal Ethic 
Committee of the First Affiliated Hospital of 
Wenzhou Medical University (approval ref no. 
2017-0003), and were in accordance with 
"Principles of Laboratory Animal Care" (NIH 




Effect of ABC294640 on CRC cells  
 
Cytotoxicity assays demonstrated that 
ABC294640 significantly decreased cell viability 
in a dose-dependent fashion in HCT-116 cells. In 
contrast, ABC294640 had marginal effect on cell 
viability in LS174T and WiDr cells, with less than 
10-fold change in viability (p < 0.001; Figure 1A). 
In addition to cytotoxicity, apoptosis was 
evaluated in the three CRC cell lines following 
ABC294640 treatment. ABC294640 treated 
HCT-116 cells displayed higher caspase 3/7 
activity relative to the untreated group (p < 0.001 
and p < 0.0001; Figure 1B). However, 
ABC294640 treatment had no effect on 
apoptosis in LS174T and WiDr cells (Figure 1B). 
These results demonstrate that HCT-116 cells 
are sensitive to ABC294640 treatment whereas 
LS174T and WiDr cells are more resistant. 
 
Upregulation of BMX in CRC cells associated 
with ABC294640 sensitivity 
 
To reveal the mechanism underlying drug 
resistance, the ABC294640-resistant cell line, 
HCT-116R, was established from HCT-116 cells 
by continuous passage in the presence of sub-
lethal doses of ABC294640. The drug 
sensitivities of HCT-116R and the parental HCT-
116 cells to ABC294640 were determined using 
the CCK8 cytotoxicity and caspase 3/7 assays. 
As shown in Figure 2 A, the half maximal 
inhibitory concentration of ABC294640 treatment 
in HCT-116 cells was 260 nM, whereas 
ABC294640 did not affect HCT-116R cell viability 
(p < 0.001). Consistently, ABC294640 increased 
the level of caspase 3/7 activity in HCT-116 cells 
p < 0.001 and p < 0.0001 while showing no effect 
in HCT-116R cells (Figure 2 B).  
 
To investigate the effect of BMX on CRC 
resistance to ABC294640, the expression of 
BMX was evaluated in drug-resistant cells and 
drug sensitive cells by qPCR and Western 
blotting. Both protein and mRNA expression 
levels of BMX were significantly higher in HCT-
116R, LS174T, and WiDr compared to HCT-116 
cells (p < 0.0001; Figure 2 C and D). 
 
Inhibition of BMX augment ABC294640 
potency in CRC 
 
To clarify the role of BMX in CRC resistance to 
ABC294640, HCT-116R, LS174T and WiDr cells 
were treated with ABC294640 in the presence or 
absence of siRNA against BMX (siBMX). Co-
treatment with siBMX and ABC294640 
significantly inhibited the cell survival of CRC 
compared to each single treatment group (p < 
0.001 and p < 0.0001; Figure 3A). In addition 
ABC294640 treatment (3 μM) and siBMX 
induced apoptosis of CRC cells 48 h post-
treatment. Combinational treatment of 
ABC294640 and siBMX dramatically enhanced 
apoptosis in CRC cells (p < 0.001 and p < 
0.0001; Figure 3B). The results indicate that 
BMX is resistance molecule during ABC294640 
treatment, and specific inhibition of BMX 
enhanced ABC294640 sensitivity in CRC cells. 
 
Figure 1: (A) Impact of ABC294640 treatment on CRC cell viability. HCT-116，LS174T, and WiDr cells were 
treated with ABC294640 (0-10 μM) for 72 h and cell survival was assessed. Relative cell survival rate was 
represented as a percentage of control group. (B) Effect of ABC294640 on caspase 3/7 activity in CRC cells. 
Cells were incubated with ABC294640 at 0.3 and 1 μM and caspase 3/7 activity evaluated. DMSO treatment was 
used as control. : WiDr; : LS174T; : HCT-116; : DMSO; :0.3 μM; : 1μM. Data represent the mean 
± SD. **p < 0.01, ##p < 0.01, and ***p < 0.001 
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Figure 2: Upregulation of BMX associated with ABC294640 sensitivity in CRC. (A) Effect of ABC294640 on 
HCT-166 and HCT-166R cell viability. HCT-116 and HCT-166R cells were incubated with ABC294640 (0-10 μM) 
for 72 h and cell survival was determined. (B) Effect of ABC294640 on caspase 3/7 activity in HCT-166 and HCT-
166R. Cells were incubated with ABC294640 at 0.3 and 1 μM and caspase 3/7 activity was evaluated. (C) mRNA 
levels of BMX in CRC cells were measured by qPCR. (D) BMX protein expression was measured by western blot 
in CRC cells. : HCT-166R; : HCT-116; : DMSO; :0.3 μM; : 1μM. Data represent mean ± SD. **p < 
0.01, ***p < 0.001, and ##p < 0.01  
 
Figure 3: Inhibition of BMX increased ABC294640 potency in vitro. CRC cells were incubated with ABC294640 
(3 μM) in the absence and presence of BMX siRNA. Cell survival (A) and apoptosis (B) were determined by 
CCK8 assay and caspase 3/7 activity assay, respectively. : DMSO; : ABC294640 3 μM; : siBMX; : 




Figure 4: Inhibition of BMX increased ABC294640 
potency in vivo. HCT-116R cells or HCT-116R in 
combination with siBMX was injected into the right 
flanks of nude mice to induce tumors. Tumors were 
measured with digital calipers to obtain an average 
size of 100-150 mm3 followed by randomization into 
treatment groups. The mice were orally administrated 
0.5 % MC (vehicle control) or ABC294640 at 5 mpk, 
once per day, respectively. Tumors were measured 3 
times weekly. Data represent mean ± SD. **p < 0.01 
 
BMX inhibition increase ABC294640 potency 
in CRC in vivo 
 
As ABC294640 treatment and knockdown of 
BMX showed an additive effect in vitro in CRC,it 
was investigated that whether this also occurred 
in vivo. As indicated in Figure 4, neither 
ABC294640 treatment nor siBMX influenced the 
HCT-116R CRC xenografts in nude mice when 
given alone. However, administration of 
ABC294640 at 5 mpk in combination with siBMX 
suppressed the growth of HCT-116R tumors (p < 
0.01). 
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There S1P rheostat determines the fate of tumor 
cells. Thus far, two isoforms of SK, SK1 and 
SK2, have been identified in humans [19]. It has 
been shown that cell proliferation and migration 
was suppressed by downregulation of SK2, 
which had a greater affect than SK1 [8]. 
Recently, phase I clinical data for ABC294640 
treatment of solid tumors, a highly specific SK2 
inhibitor, have demonstrated variable clinical 
activity, which may reflect either the lack of 
biomarkers for patient selection and/or deficiency 
of knowledge about drug-resistant mechanisms 
[20]. In the current study, the molecular target 
that contributes to the limited therapeutic efficacy 
of ABC294640 in CRC was investigated. 
 
ABC294640 has been extensively studied for the 
treatment of many human tumor types and 
animal tumor models including CRC. 
ABC294640 suppressed cell proliferation and 
induced cell apoptosis in CRC cells in vitro. 
ABC294640 treatment remarkably inhibited HT-
29 tumor growth in vivo, suggesting that 
ABC294640 might be an effective anti-tumor 
drug in CRC [21]. In the current study, 
ABC294640 sensitivity in several CRC cell lines 
was tested, with variable effects among these 
cell lines, consistent with its clinical activity. This 
indicates the presence of intrinsic CRC 
resistance to ABC294640. 
 
Bone marrow kinase in chromosome X is 
reported to be overexpressed in various tumor 
types [22]. It also participates in drug resistance 
as it suppresses the apoptotic regulator BAK 
activation via phosphorylation, which facilitates 
the survival of cells subjected to cytotoxic agents 
[23]. Bone marrow kinase in chromosome X also 
is suggested to protect prostate cancer cells from 
photodynamic induced apoptosis [24]. In 
addition, suppressing BMX expression reduced 
the chemo-resistance of H69/AR cells [25]. In 
this study, BMX mRNA and protein expression 
were increased in ABC294640-resistant CRC 
cells and silencing BMX down-regulated cell 
sensitivity to ABC294640 in ABC294640-
resistant cells. Further, knockdown of BMX 
enhanced the effect of ABC294640 treatment on 
tumor growth both in vitro and in vivo. These 
findings suggest that BMX upregulation 





These findings demonstrate that BMX 
upregulation impedes the antitumor effect of 
ABC294640 in CRC cells, and knockdown of BM 
augments ABC294640 ability to suppress the 
tumor growth of CRC in vitro and in vivo. 
Therefore, these data may present a novel 
therapeutic strategy for the CRC therapy using a 
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